Author

E. A. Toth

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Bioengineering· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 2 Assay:protein sequence· 1

Frequent Co-Authors

T. R. Fuerst· 3 shared R. Wang· 2 shared A. K. Andrianov· 1 shared A. Marin· 1 shared B. G. R. Voldborg· 1 shared B. Pierce· 1 shared B. Ruan· 1 shared D. A. Rozak· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBioengineering

T. R. Fuerst

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Glycoengineered recombinant alpha1-antitrypsin results in comparable in vitro and in vivo activities to human plasma-derived protein

F. Rocamora, S. Schoffelen, J. Arnsdorf, E. A. Toth, Y. Abdul, T. E. Cleveland, S. P. Bjorn, M. Y. M. Wu, N. G. McElvaney, B. G. R. Voldborg, T. R. Fuerst, N. E. Lewis

This study generates glycoengineered recombinant alpha1-antitrypsin with in vitro and in vivo activities comparable to plasma-derived A1AT, offering a sustainable therapeutic alternative.

bioRxiv · Mar 27, 2024 · PreprintBioengineering

Engineering protein-specific proteases: targeting active RAS

Y. Chen, E. A. Toth, B. Ruan, E. J. Choi, R. Simmerman, Y. Chen, Y. He, R. Wang, R. Godoy-Ruiz, H. King, G. Custer, D. T. Gallagher, D. A. Rozak, M. Soloman, S. Muro, , P. N. Bryan

This study designs engineered proteases that specifically degrade active RAS by cleaving a conserved sequence in switch 2, showing efficacy in vitro and in human cell culture.

bioRxiv · Sep 21, 2020Biochemistry

Structure-based design of hepatitis C virus E2 glycoprotein improves serum binding and cross-neutralization

B. Pierce, Z.-y. Keck, R. Wang, P. Lau, K. J. Garagusi, K. Elkholy, E. A. Toth, R. A. Urbanowicz, J. D. Guest, P. Agnihotri, M. C. Kerzic, A. Marin, A. K. Andrianov, J. K. Ball, R. Mariuzza, , S. Foung

The paper designs optimized HCV E2 glycoproteins to enhance binding and cross-neutralization by modifying antigenic sites and testing immunogenicity in mice.

bioRxiv · Apr 15, 2020Microbiology